Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151591 · ClinicalTrials.gov registry record · Phase 1
New Approaches to Smoking Cessation in Heavy Drinkers
A Phase 1 study of Nicotine Dependence and Cigarette Smoking, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02151591: Completed Phase 1 study of Nicotine Dependence and Cigarette Smoking, sponsored by Yale University.
NCT02151591 is a Phase 1 study of Nicotine Dependence and Cigarette Smoking that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02151591, a Phase 1 study of Nicotine Dependence and Cigarette Smoking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and test an integrated cognitive-behavioral intervention for smoking and alcohol among heavy drinking smokers. The current pre-pilot phase will be used to refine this protocol for the subsequent randomized, controlled pilot phase. The current study phase has two parts: 1) an intake session and brief physical; 2) a 12-week treatment phase in which participants receive varenicline (Chantix) and weekly, personalized counseling.
Primary Outcome
Number of participants with point prevalence smoking abstinence (i.e., no smoking, not even a puff over the last 7 days) 6 months after treatment completion.
Conditions Studied
Interventions
- DRUG Varenicline
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 1 |
What the finished NCT02151591 record still lists
NCT02151591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Varenicline is the first listed.
NCT02151591 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02151591 about?
NCT02151591 is a clinical study titled "New Approaches to Smoking Cessation in Heavy Drinkers". The purpose of this study is to develop and test an integrated cognitive-behavioral intervention for smoking and alcohol among heavy drinking smokers. The current pre-pilot phase will be used to refine this protocol for the subsequent randomized, controlled pilot phase. The current study phase has t...
What is the current status of trial NCT02151591?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-03-01. Estimated completion is 2018-08-01.
What conditions does trial NCT02151591 study?
This clinical trial studies the following conditions: Nicotine Dependence, Cigarette Smoking, Alcohol Consumption, Heavy Drinking.
What interventions are being tested in trial NCT02151591?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT02151591?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02151591 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02151591's enrollment target sits among peer trials
26 55th of 67 higher than 13 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
-
Brain Reaction to Treatment of Nicotine Dependence
COMPLETED · Phase 1
-
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
COMPLETED · Phase 1
-
Nicotine Differences in Smokers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI